作者
Jonathan M Meyer, Vicki G Davis, Donald C Goff, Joseph P McEvoy, Henry A Nasrallah, Sonia M Davis, Robert A Rosenheck, Gail L Daumit, John Hsiao, Marvin S Swartz, T Scott Stroup, Jeffrey A Lieberman
发表日期
2008/4/1
期刊
Schizophrenia research
卷号
101
期号
1-3
页码范围
273-286
出版商
Elsevier
简介
BACKGROUND
The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial.
METHODS
The change in proportion of subjects with MS and individual criteria was compared between antipsychotic treatment groups, along with mean changes for individual criteria. Primary analyses examined subjects with fasting laboratory assessments at baseline and 3 months. Other analyses examined 3-month changes in MS status, waist circumference (WC), HDL cholesterol and blood pressure in all subjects, metabolic changes at the end of phase 1 participation (EOP), and repeated measures changes in HDL, blood pressure (BP) and WC over phase 1.
RESULTS
At 3 months …
引用总数
学术搜索中的文章
JM Meyer, VG Davis, DC Goff, JP McEvoy… - Schizophrenia research, 2008